Latest / Stock Movers / AstraZeneca Climbs, Vodafone Gains, Pinewood Surges
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Now, let's take a look at some of the stocks
- 0:18Speaker 3: on the move today in Europe. I'm Lizzie Burden in
- 0:20Speaker 3: London with Stephen Carroll in Brussels, and we're joined by
- 0:22Speaker 3: Bloomberg's Breaking News editor, Louise Moon. Louise, I want to
- 0:25Speaker 3: start with tech and a search for Pinewood.
- 0:28Speaker 1: Yeah, so there was news late on Friday, after the
- 0:31Speaker 1: close that Pinewood, which is a tech firm, had received
- 0:35Speaker 1: a take of a bid from Ridgewood Partners that's for
- 0:38Speaker 1: five hundred and forty five million pounds. So, as I say,
- 0:42Speaker 1: that offer came after close on Friday. Ridgewood is a
- 0:45Speaker 1: private acuity firm. It's based in San Francisco and it's
- 0:47Speaker 1: very tech focused. And then Pinewood the company in London.
- 0:52Speaker 1: It used to be called Pendragon, which you might recognize
- 0:54Speaker 1: it ruand car dealerships. That business was sold off in
- 0:56Speaker 1: twenty twenty four and it's turned more towards software, so
- 0:59Speaker 1: it's software for car dealers and manufacturers. So that's been
- 1:04Speaker 1: offered takeover off of the prices of forty three percent
- 1:06Speaker 1: premium to their closing before this offer, and then shares
- 1:09Speaker 1: reacted this morning, which is why we're talking about it
- 1:11Speaker 1: this morning, So shares up as much as thirty five percent,
- 1:13Speaker 1: so just slightly blow that offer price. So we're waiting
- 1:17Speaker 1: to steal if this seat, if this deal comes through.
- 1:19Speaker 1: If it does, it's obviously another company from London listed
- 1:23Speaker 1: in London going to a US firm and US privateity,
- 1:27Speaker 1: and it also would be a tech company leaving London,
- 1:29Speaker 1: which London already lacks a lot of tech companies, so
- 1:32Speaker 1: it would be one of the kind of few ones,
- 1:34Speaker 1: even if it is a relatively small company that could
- 1:37Speaker 1: potentially leave if this deal comes through.
- 1:39Speaker 2: Okay, so that's on pine Wood. Meanwhile, Vodafone reporting earnings
- 1:43Speaker 2: this morning and shares a little higher hope, go get
- 1:46Speaker 2: me higher. Actually four percent?
- 1:48Speaker 1: I just yeah number there you go, yeah, of about
- 1:50Speaker 1: four percent after their third quarter results. So revenue grew
- 1:53Speaker 1: more than expected. Four your guidance for a couple of
- 1:56Speaker 1: factors raised to the higher end of their rangers. And
- 2:00Speaker 1: this is all mostly down to growth in Germany, which
- 2:03Speaker 1: is Vodafone's largest market, and that was quite a positive
- 2:05Speaker 1: surprise un List had forecasts almost no growth in that sector.
- 2:10Speaker 1: It's quite a kind of a win, I guess you
- 2:12Speaker 1: could say for the CEO her efforts to rejuvenate the business.
- 2:16Speaker 1: She's been selling underperforming units, cutting jobs and also boltering
- 2:20Speaker 1: those key markets, so like Germany, trying to grow those
- 2:24Speaker 1: as well. So it's a good indicator of that. And
- 2:28Speaker 1: as I say, other things as well, you know, cost
- 2:29Speaker 1: controls and the like. So i'd say shares rows. That's
- 2:33Speaker 1: adding to gains over the past year. They've gained about
- 2:36Speaker 1: thirty percent over the past year, so kind of reflecting
- 2:39Speaker 1: shareholders welcoming those efforts by the CEO. But if you
- 2:41Speaker 1: do look back, they are still far off their all
- 2:44Speaker 1: time high, so still some work to be done to
- 2:47Speaker 1: return to those but some positive indicators for Vodaphone and
- 2:50Speaker 1: it's turnaround efforts there.
- 2:53Speaker 3: Just finally, earnings wise, AstraZeneca profit growth based on its
- 2:56Speaker 3: cancer drugs tell us more.
- 2:58Speaker 1: Yes, so second quarter profit higher then it's inspected. They
- 3:00Speaker 1: confirm guidance for the year as well as twenty thirty targets.
- 3:03Speaker 1: As you say, on the back of their cancer drugs.
- 3:05Speaker 1: They've turned themselves into a bit of a kind of
- 3:07Speaker 1: cancer drug powerhouse and this is paying off, so particularly
- 3:11Speaker 1: a lot of demand for its breast cancer drug as well.
- 3:15Speaker 1: There are some pressures there, so for example, they lost
- 3:19Speaker 1: exclusivity rights in the US for one of their drugs,
- 3:22Speaker 1: but their cancer drugs and the growth there is offsetting
- 3:25Speaker 1: those pressures, so good results on that front. Investors are
- 3:29Speaker 1: now focusing on whether that success in oncology can continue.
- 3:32Speaker 1: So there's quite a few late stage clinical trial results
- 3:36Speaker 1: set for later this year and those are quite key,
- 3:39Speaker 1: so those will be a close focus going forward. But
- 3:42Speaker 1: for today, he shares rows trimming some of the declines
- 3:45Speaker 1: for the year so far. So a good positive update
- 3:48Speaker 1: there from Asha Seneca.
- 3:50Speaker 2: The Stock Movers report from Bloomberg Radio. Check back with
- 3:54Speaker 2: us throughout the day for the latest roundup of companies
- 3:57Speaker 2: making news on Wall Street and for the latest market
- 4:00Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 4:05Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 4:08Speaker 2: the Bloomberg Business app.